How much funding did Moderna receive from CEPI?

Moderna secured up to US$50 million from CEPI for its Bundibugyo ebolavirus vaccine candidate.

Why are these developments important for Moderna?

They demonstrate the versatility of the mRNA platform beyond COVID-19, opening new markets in oncology and infectious diseases.

Moderna and Merck Report Positive mRNA Cancer Vaccine Data

Q: What were the Phase 2b results?

Five-year data showed the vaccine substantially reduced the risk of cancer recurrence, metastasis, and death compared to Keytruda alone.

Moderna and Merck announced positive five-year Phase 2b data for their personalized mRNA melanoma vaccine, showing reduced risk of cancer recurrence and death. Additionally, Moderna secured up to $50 million from CEPI for its ebolavirus vaccine candidate.

June 7, 2026

1 min read

Source: Simply Wall St.

Key Numbers

funding

US$50.00 million

phase

Phase 2b

Moderna (MRNA) and Merck (MRK) reported five-year Phase 2b data demonstrating that their personalized mRNA melanoma vaccine, intismeran autogene, combined with Keytruda, substantially reduced the risk of cancer recurrence, metastasis, and death compared to Keytruda alone.

Details

The results highlight the potential of mRNA technology in oncology. Separately, Moderna secured up to US$50 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for its Bundibugyo ebolavirus mRNA vaccine candidate, underscoring the platform's versatility.

Context

These developments come as Moderna continues to expand its pipeline beyond COVID-19 vaccines. The positive cancer data could bolster investor confidence in the company's long-term prospects.

What This Means for Investors

While the data is encouraging, regulatory approvals and further trials are needed. Investors should monitor upcoming milestones and regulatory decisions.

Frequently Asked Questions

It is a personalized mRNA melanoma vaccine developed by Moderna and Merck, used in combination with Keytruda.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.